In Re Inter-Op Hip Prosthesis Product Liability Litigation

174 F. Supp. 2d 648, 2001 U.S. Dist. LEXIS 19967, 2001 WL 1540552
CourtDistrict Court, N.D. Ohio
DecidedSeptember 17, 2001
Docket1:01-CV-9000
StatusPublished
Cited by2 cases

This text of 174 F. Supp. 2d 648 (In Re Inter-Op Hip Prosthesis Product Liability Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Inter-Op Hip Prosthesis Product Liability Litigation, 174 F. Supp. 2d 648, 2001 U.S. Dist. LEXIS 19967, 2001 WL 1540552 (N.D. Ohio 2001).

Opinion

MEMORANDUM AND ORDER

O’MALLEY, District Judge.

Defendants move for an Order enjoining related state-court litigation (docket no. 71). The plaintiffs do not oppose the motion. Other interested parties, however, have objected to the entry of the requested injunctive relief. 1

For the reasons stated below, the defendants’ motion is GRANTED . Accordingly, the Court hereby ENJOINS: (a) any and all persons from commencing or continuing prosecution (b) of any claim or action or legal proceeding (c) in any federal, state, or territorial court (d) against the “Sulzer Defendants” 2 or their assets (e) related in any way to claims arising out of an alleged product defect in Sulzer Orthopedic, Inc.’s Inter-Op acetabular shell hip implant.

This injunction shall remain in force until further Order of the Court. The Court retains jurisdiction to: (1) modify or vacate this injunction if circumstances change; and (2) lift the injunction as it applies to any person prosecuting any given legal proceeding, for good cause shown, on a case-by-case basis.

The parties are ORDERED to notify any interested party of this Order, as soon as and to the fullest extent reasonably possible.

I. Background.

As described more fully in the Court’s Order dated August 31, 2001, this case revolves around the manufacture and distribution by defendant Sulzer Orthopedics, Inc. of an orthopedic hip implant known as the “Inter-Op Acetabular shell.” Sulzer Orthopedics recalled approximately 40,000 units of its Inter-Op shell because of an *651 alleged manufacturing defect; about 26,-000 of the Inter-Op shells had already been implanted in patients, and it is estimated that about 4,500 of these patients will have to have “revision surgery” to remove and replace the defective implants.

To date, there are pending about 1,580 civil suits nationwide, brought by plaintiffs against Sulzer Orthopedics and related entities. About 220 of these suits are in federal court. The Federal Judicial Panel on Multi-District Litigation (“MDL Panel”) consolidated and transferred all related pending federal litigation to the Northern District of Ohio and assigned oversight of the MDL proceedings to the undersigned. Thus, virtually all of the federal cases involving the Inter-Op acetabular shell have either been transferred to this Court or are in the process of being transferred to this Court.

The 1,580 state and federal cases involve about 2,000 named plaintiffs, primarily including implant recipients and their spouses. Over 90% of the state court actions have been filed in California, Texas, Florida, or New York. About 19 of the state court cases are styled as class actions, as are about 34 of the federal court cases. The defendants named in these lawsuits include not only Sulzer Orthopedics, but also: (1) Sulzer Medica USA Holding Company (“Sulzer Medica USA”), a holding company that owns Sulzer Orthopedics; (2) Sulzer Medica Ltd., a Swiss holding company that owns Sulzer Medica USA; (3) Sulzer AG, a Swiss company that previously owned a majority of the stock of Sulzer Medica Ltd.; (4) various other Sulzer-related entities; and (5) various surgeons, hospitals, and medical supply companies connected to the distribution or implantation of the defective product. The causes of action in these lawsuits include claims for defective design, marketing and manufacture; breach of express and implied warranties; negligence; strict liability; and other legal theories of recovery. At least one state court case has been tried, resulting in a $15 million verdict against Sulzer Orthopedics. 3 About 40 of these state-court actions are set for trial before the end of the calendar year.

After this Court appointed temporary liaison and co-lead counsel to represent the plaintiffs in the MDL proceedings, plaintiffs’ counsel filed an “amended and consolidated class action complaint.” In addition, plaintiffs’ counsel filed a motion for conditional class certification, and for preliminary approval of the proposed class settlement agreement. The defendants also filed a motion for preliminary approval of the proposed class settlement agreement. On August 29, 2001, the Court entered an Order essentially granting these motions — the Court conditionally certified a settlement class, 4 preliminarily approved *652 the proposed class settlement agreement, 5 and preliminarily appointed class co-counsel.

At the same time that the plaintiffs and defendants filed their motions for conditional class certification and preliminary approval of the settlement agreement, they also filed motions for an Order enjoining all other litigation involving the Inter-Op shells from proceeding. The Court later granted the parties’ joint oral motion to voluntarily withdraw these motions, without prejudice. With their most recent motion, the defendants now renew their original request for injunctive relief. As noted above, however, before the parties withdrew their original motions for injunctive relief, the Court invited any person (including persons not parties to any federal proceeding) wishing to object to the pending motions to submit their comments in writing. The Court received about 41 such comments. The Court has reviewed all of these comments in detail, once again, during the course of its consideration of the defendants’ renewed motion for injunctive relief.

On September 13, 2001, following its entry of the Order conditionally certifying the settlement class and preliminarily approving the proposed class settlement agreement, the Court entered its Case Management Order (“CM Order”). Among other things, the CM Order: (1) set forth a very aggressive schedule for discovery, which is to be directed primarily at the issue of the fairness of the proposed settlement agreement; (2) created a mechanism ensuring that counsel representing plaintiffs in various related state court actions will participate in this MDL discovery, and share in review of all MDL discovery; (3) set forth a schedule for issuance of notice to the class; (4) arranged for the Court to meet with the parties monthly (at a minimum) to assess the progress of the case and to resolve any disputes; and (5) set dates for the final fairness hearing and for submission of objections to the final proposed settlement agreement. The defendants filed their pending motion for an Order enjoining related litigation four days later, on September 17, 2001 — two days before a related California state court case is scheduled to begin trial.

II. Legal Standards and Analysis.

There are two statutes that govern the propriety of a federal district court’s issuance of an order enjoining state court litigation: the Anti-Injunction Act, and the All-Writs Act. Under the terms of the Anti Injunction Act, “[a] court of the United States may not grant an injunction to stay proceedings in a State court except [1] as expressly authorized by Act of Congress, or [2] where necessary in aid of its jurisdiction, or [3] to protect or effectuate its judgments.” 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hanover Am. Ins. Co. v. Tattooed Millionaire
38 F.4th 501 (Sixth Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
174 F. Supp. 2d 648, 2001 U.S. Dist. LEXIS 19967, 2001 WL 1540552, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-inter-op-hip-prosthesis-product-liability-litigation-ohnd-2001.